HealthStream, Inc. (NASDAQ:HSTM) Receives $28.00 Average Target Price from Analysts

HealthStream, Inc. (NASDAQ:HSTM) has earned an average rating of “Hold” from the five research firms that are covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $25.00.

HSTM has been the subject of a number of research reports. Canaccord Genuity Group set a $25.00 price objective on HealthStream in a research note on Thursday. Citigroup reiterated a “market perform” rating on shares of HealthStream in a report on Tuesday. Wall Street Zen downgraded shares of HealthStream from a “buy” rating to a “hold” rating in a research report on Saturday, November 22nd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of HealthStream in a research note on Wednesday, October 8th.

Insider Activity

In other HealthStream news, EVP Kevin P. O’hara sold 2,000 shares of the firm’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $24.26, for a total transaction of $48,520.00. Following the transaction, the executive vice president directly owned 16,373 shares in the company, valued at approximately $397,208.98. This trade represents a 10.89% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CTO Jeff Cunningham sold 2,100 shares of HealthStream stock in a transaction on Wednesday, December 10th. The stock was sold at an average price of $24.09, for a total transaction of $50,589.00. Following the transaction, the chief technology officer directly owned 31,489 shares in the company, valued at $758,570.01. This represents a 6.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 5,680 shares of company stock worth $139,336 over the last 90 days. 20.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On HealthStream

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Robeco Institutional Asset Management B.V. boosted its stake in HealthStream by 162.1% in the second quarter. Robeco Institutional Asset Management B.V. now owns 380,604 shares of the technology company’s stock valued at $10,531,000 after acquiring an additional 235,382 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of HealthStream by 302.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 247,905 shares of the technology company’s stock worth $6,860,000 after purchasing an additional 186,231 shares during the last quarter. Copeland Capital Management LLC raised its holdings in shares of HealthStream by 15.6% in the 2nd quarter. Copeland Capital Management LLC now owns 882,950 shares of the technology company’s stock worth $24,431,000 after purchasing an additional 119,260 shares during the period. Qube Research & Technologies Ltd lifted its stake in HealthStream by 77.3% in the second quarter. Qube Research & Technologies Ltd now owns 251,953 shares of the technology company’s stock valued at $6,972,000 after purchasing an additional 109,883 shares during the last quarter. Finally, Numerai GP LLC purchased a new position in HealthStream in the third quarter valued at approximately $1,911,000. 69.58% of the stock is owned by hedge funds and other institutional investors.

HealthStream Trading Down 2.0%

HSTM opened at $22.30 on Tuesday. The company has a fifty day moving average price of $24.31 and a two-hundred day moving average price of $26.21. HealthStream has a 1-year low of $22.26 and a 1-year high of $34.24. The company has a market cap of $661.64 million, a P/E ratio of 32.79, a price-to-earnings-growth ratio of 2.46 and a beta of 0.43.

HealthStream (NASDAQ:HSTM) last released its quarterly earnings data on Monday, November 3rd. The technology company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.17 by $0.03. HealthStream had a net margin of 6.93% and a return on equity of 5.82%. The company had revenue of $76.47 million for the quarter, compared to analysts’ expectations of $75.52 million. On average, research analysts forecast that HealthStream will post 0.63 EPS for the current fiscal year.

HealthStream Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, November 28th. Stockholders of record on Monday, November 17th were given a dividend of $0.031 per share. The ex-dividend date of this dividend was Monday, November 17th. This represents a $0.12 annualized dividend and a dividend yield of 0.6%. HealthStream’s payout ratio is presently 17.65%.

HealthStream announced that its Board of Directors has approved a share repurchase program on Tuesday, November 11th that authorizes the company to buyback $10.00 million in shares. This buyback authorization authorizes the technology company to purchase up to 1.3% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board believes its stock is undervalued.

About HealthStream

HealthStream, Inc is a Nashville, Tennessee–based provider of workforce development and learning management solutions for healthcare organizations. Since its founding in 1990, the company has focused on helping hospitals, clinics and other care providers streamline staff training, ensure regulatory compliance and monitor employee performance. HealthStream’s platform integrates online courses, skill competency assessments and credential management tools to support workforce readiness across the healthcare continuum.

The company’s core offerings include a learning management system (LMS) designed specifically for clinical and nonclinical personnel, a competency management suite that tracks skill acquisition and validation, and a content library featuring evidence-based clinical and compliance training modules.